Atlas Trials

A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical trial NCT06839872 · WITHDRAWN

Trial details

NCT number
NCT06839872
Sponsor
AstraZeneca
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2025-06-30
Primary completion
2028-07-28
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.